Trial Profile
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Tacrolimus
- Indications Liver transplant rejection; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms REDUCE
- Sponsors Novartis
- 01 Jun 2022 Primary endpoint (Glomerular filtration rate) has not been met according to the results published in the Revista Espanola de Enfermedades Digestivas
- 01 Jun 2022 Results assessing the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain published in the Revista Espanola de Enfermedades Digestivas
- 27 Sep 2017 52-Weeks results presented at the 18th Congress of the European Society for Organ Transplantation